Patients and Methods
We recruited ten Japanese patients with type 2 diabetes mellitus, whose fasting glucose levels remained poorly controlled under meal-time injection of shortacting insulin. Their fasting glucose levels remained higher than bedtime glucose levels, even after insulin was titrated enough to keep their bedtime glucose levels below 7.8 mmol/L. Metformin was then added to their insulin therapy, and was titrated to a maximum dose of 500 mg. The medication was taken once a day, at bedtime. We assessed HGP and PGU, as well as their fasting glucose levels, before and one week after metformin treatment. HGP and PGU were evaluated with the use of [6,6-2 H 2 ] glucose. In brief, [6,6-2 H 2 ]glucose was infused for 120 minutes (a bolus infusion at 0.3 mg/kg/min for 10 minutes and a subsequent steady infusion at 0.05 mg/kg/min for 110 minutes), and blood samples were obtained. Its enrichment in plasma was analyzed by gas chromatography/mass spectrometry, after trifluoroacetylation of glucose [4] . We performed 
Discussion
It was long pointed out that metformin was effective in Asian patients, even in a low dose [5] , but its mechanism remained unknown. Our current study revealed that efficacy of metformin on correcting fasting hyperglycemia was strongly associated with reduced HGP, rather than ameliorated PGU, in Japanese patients, as observed in Caucasians. Given that an impaired HGP suppression was observed in lean Japanese patients and was significantly associated with fasting hyperglycemia [4] , these findings would support the validity of metformin therapy in Japanese patients to target at their underlying pathogeneses. In conclusion, low dose of metformin significantly reduced hepatic glucose production in Japanese patients with type 2 diabetes mellitus. The efficacy of metformin on correcting fasting hyperglycemia was strongly associated with reduced hepatic glucose production, rather than ameliorated peripheral glucose uptake. the current study in accordance with the declaration of Helsinki, and it was approved by the ethics committee of Osaka University. We obtained written informed consent from all the recruited patients. Statistical analyses were performed using IBM SPSS Statistics Version 19 (SPSS Inc., IL, USA). Data are presented as medians and quartiles. A p value was assessed with nonparametric procedures because of the small sample size and the uncertainty about data distribution.
results
Six patients were male and four were female. They were 56 (52, 60) years old, and their body mass index was 26.7 (22.8, 30.9) kg/m 2 (medians and quartiles). Their waist circumference was 101 (92, 108) cm; eight of ten had an increased waist circumference, defined as ≥ 85 cm in males and ≥ 90 cm in females. The baseline fasting glucose level were 8.3 (7.1, 9.0) mmol/L under multiple short-acting insulin injection. Triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol levels were 1.7 (1.4, 2.0) mmol/L, 1.3 (1.0, 1.5) mmol/L, and 3.4 (3.0, 4.1) mmol/L, respectively.
Fasting glucose levels and HGP were significantly improved after the metformin treatment (p < 0.01 and 0.02), whereas their PGU was not significantly changed (p = 0.63) (Table 1) . Furthermore, the change of fasting glucose levels was significantly correlated with that of HGP, whose coefficient ρ was 0.76 (p = 0.01). On the other hand, there was no significant correlation between 
